Significance of TP53 mutations as predictive markers of adjuvant cisplatin‐based chemotherapy in completely resected non‐small‐cell lung cancer

Adjuvant cisplatin‐based chemotherapy only marginally improves survival in patients with completely resected non‐small‐cell lung cancer (NSCLC). We have evaluated the predictive value of mutations in TP53, encoding the tumour suppressor p53, in the International Adjuvant Lung Cancer Trial (IALT), a...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Mol Oncol
Autori principali: Ma, Xiaoli, Rousseau, Vanessa, Sun, Haiji, Lantuejoul, Sylvie, Filipits, Martin, Pirker, Robert, Popper, Helmut, Mendiboure, Jean, Vataire, Anne-Lise, Le Chevalier, Thierry, Soria, Jean Charles, Brambilla, Elisabeth, Dunant, Ariane, Hainaut, Pierre
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2014
Soggetti:
Research Articles
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528648/
https://ncbi.nlm.nih.gov/pubmed/24495481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2013.12.015
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi